Researchers have revealed a groundbreaking molecular glue capable of tricking cancer cells into "self-destructing," in a move that could represent a revolution in the treatment of kidney cancer.
California-based medical startup Neomorph announced the start of its first clinical trials for NEO-811, a drug designed to treat clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer in the United States.
The drug NEO-811 works by directing enzymes known as E3 ubiquitin ligases to destroy harmful proteins, stimulating cancer cells to self-destruct.
The first dose of the drug, known as a "molecular glue dissolver," was administered to a patient as part of a Phase I/II trial. This drug consists of a group of small molecules that trigger a reaction between the disease-causing protein and destructive enzymes, forcing cancer cells to self-destruct and preventing the disease from spreading or worsening. These drugs are typically given orally in multiple doses.
Neomorph explains that this molecular glue differs from traditional treatments like chemotherapy in that it redirects the body to eliminate harmful proteins on its own by classifying them as "waste." This could help reduce the long-term side effects of chemotherapy and radiation, such as neuropathy, organ damage, and infertility.
Dr. Phil Chamberlain, CEO and founder of NeoMorph, said: "Administering the first dose to the patient represents a turning point for our company, as it is the first clinical evaluation of a drug we developed in-house. We look forward to gathering data that will help develop NEO-811 and enhance our platform's ability to deliver innovative medicines to patients with unmet medical needs."
Clear cell carcinoma begins in the cells responsible for filtering waste products from the blood. The exact causes are still unclear, but smoking, alcohol consumption, and inhaling toxins from certain types of mold increase the risk.
Neomorph chose to focus on clear cell renal cell carcinoma because most patients have a mutation in the VHL gene that stimulates tumor growth, making this type an obvious target for precision therapies. (VHL acts as a tumor suppressor protein, meaning it protects cells from uncontrolled growth that could lead to cancer.)
The company is seeking to expand its research to include other types of tumors, which have not yet been specified.
The date when more patients will receive the drug, and the timing of the announcement of clinical trial results, are still undetermined.
